CN115443148B - 鼻内mRNA疫苗 - Google Patents

鼻内mRNA疫苗 Download PDF

Info

Publication number
CN115443148B
CN115443148B CN202180009112.1A CN202180009112A CN115443148B CN 115443148 B CN115443148 B CN 115443148B CN 202180009112 A CN202180009112 A CN 202180009112A CN 115443148 B CN115443148 B CN 115443148B
Authority
CN
China
Prior art keywords
mrna
mrna molecules
infection
antigen
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202180009112.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN115443148A (zh
Inventor
W·泰斯特
D·梵霍里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ezer Arne Immunotherapy Co ltd
Original Assignee
Ezer Arne Immunotherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ezer Arne Immunotherapy Co ltd filed Critical Ezer Arne Immunotherapy Co ltd
Publication of CN115443148A publication Critical patent/CN115443148A/zh
Application granted granted Critical
Publication of CN115443148B publication Critical patent/CN115443148B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180009112.1A 2020-02-14 2021-02-15 鼻内mRNA疫苗 Expired - Fee Related CN115443148B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20157300 2020-02-14
EP20157300.3 2020-02-14
PCT/EP2021/053633 WO2021160881A1 (en) 2020-02-14 2021-02-15 Intranasal mrna vaccines

Publications (2)

Publication Number Publication Date
CN115443148A CN115443148A (zh) 2022-12-06
CN115443148B true CN115443148B (zh) 2024-08-06

Family

ID=69593570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180009112.1A Expired - Fee Related CN115443148B (zh) 2020-02-14 2021-02-15 鼻内mRNA疫苗

Country Status (13)

Country Link
US (1) US20230071518A1 (https=)
EP (1) EP4103226A1 (https=)
JP (1) JP2023518340A (https=)
KR (1) KR20230004447A (https=)
CN (1) CN115443148B (https=)
AU (1) AU2021219304A1 (https=)
BR (1) BR112022015666A2 (https=)
CA (1) CA3170239A1 (https=)
IL (1) IL295507A (https=)
MX (1) MX2022009943A (https=)
TW (1) TW202144002A (https=)
WO (1) WO2021160881A1 (https=)
ZA (1) ZA202209779B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023037320A1 (en) * 2021-09-10 2023-03-16 Intron Biotechnology, Inc. Mucosal messenger rna vaccine
JP2024545093A (ja) * 2021-12-08 2024-12-05 イェール ユニバーシティー 細胞および組織に標的化するためのポリ（アミン－ｃｏ－エステル）ナノ粒子への表面コンジュゲーション
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3453754A1 (en) * 2012-08-23 2019-03-13 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
CN110352071A (zh) * 2016-10-26 2019-10-18 库瑞瓦格股份公司 脂质纳米颗粒mRNA疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058792T2 (hu) * 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
PL4023249T3 (pl) * 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
EP4011451A1 (en) * 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
CA3088485A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3453754A1 (en) * 2012-08-23 2019-03-13 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
CN110352071A (zh) * 2016-10-26 2019-10-18 库瑞瓦格股份公司 脂质纳米颗粒mRNA疫苗

Also Published As

Publication number Publication date
BR112022015666A2 (pt) 2022-09-27
CA3170239A1 (en) 2021-08-19
AU2021219304A1 (en) 2022-10-06
MX2022009943A (es) 2022-10-18
WO2021160881A9 (en) 2022-11-10
TW202144002A (zh) 2021-12-01
US20230071518A1 (en) 2023-03-09
WO2021160881A1 (en) 2021-08-19
IL295507A (en) 2022-10-01
EP4103226A1 (en) 2022-12-21
ZA202209779B (en) 2024-01-31
JP2023518340A (ja) 2023-05-01
KR20230004447A (ko) 2023-01-06
CN115443148A (zh) 2022-12-06

Similar Documents

Publication Publication Date Title
CN115443148B (zh) 鼻内mRNA疫苗
CN116390752A (zh) 自扩增性sars-cov-2rna疫苗
JP2023551982A (ja) マルチシストロン性ｒｎａワクチン及びその使用
Bai et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
US20230173058A1 (en) Sars-cov-2 vaccine
JPH11507510A (ja) インフルエンザの新規組換え温度感受性変異体
WO2022110099A1 (en) Coronavirus vaccines and uses thereof
TW202417016A (zh) 冠狀病毒疫苗
US20230105376A1 (en) Piv5-based coronavirus vaccines and methods of use thereof
CN117815377A (zh) mRNA的用途
CN117899208A (zh) 冠状病毒疫苗
CN119350507A (zh) 新型流感纳米颗粒疫苗及其制备与应用
HK40085781A (en) Intranasal mrna vaccines
TW202400800A (zh) 用於預防和治療狂犬病毒感染的組合物和方法
US20250032603A1 (en) Expression of the spike s glycoprotein of sars-cov-2 from avian paramyxovirus type 3 (apmv3)
Singh et al. Current Insights on Vaccines available for COVID-19 like Flu Symptoms
EP4574168A1 (en) Prime-boost immunization against influenza
RU2843610C1 (ru) Полинуклеотидная вакцина и способ струйной безыгольной ее доставки в организм
US20240287544A1 (en) Modified piv5 vaccine vectors: methods of making and uses
WO2025179238A2 (en) Coronavirus vaccine
KR20250080759A (ko) 교차 면역원성을 갖는 b형 인플루엔자 바이러스 및 이를 포함하는 백신
WO2025147639A1 (en) Improved formulation providing increased stability for vaccines composition
CN121620388A (zh) 针对猪流行性腹泻的病毒载体重组疫苗
CN121773126A (zh) 疫苗组合物
CN118632708A (zh) 基于piv5的冠状病毒疫苗及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085781

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240806

CF01 Termination of patent right due to non-payment of annual fee